Few millions of HCV patients participated in a nation-wide study debating on the cost expense of treatment. The results were a win-win as "administering less expensive regimens to non-cirrhotic patients and expensive yet more effective regimens to cirrhotic patients resulted in optimal outcomes for patients and insurers."